What is it about?
There is a complicated mechanistic interaction between the cancer cells and the tumor microenvironments. The “one-stone-two-birds” strategy was developed by using a mannosylated albumin nanoparticulate codelivery system to dual-target the cancer cells and M2 macrophages via the pathways of both mannose receptors and the albumin-binding protein SPARC, resulting in M2 macrophage modulation and enhanced cytotoxicity on the MDR cancer cells.
Featured Image
Why is it important?
Drug resistance is the major hurdle against effective cancer therapy. The authors found that disulfiram, an alcohol-abuse drug already for over six decades, in combination with a multi-kinase inhibitor regorafenib, can re-educate the tumor-associated macrophage, promoting its switch from the "bad" M2 phenotype to the "good" M1, and simultaneously target the cancer cells, thus overcoming the drug resistance and improving the cancer therapeutic outcomes.
Perspectives
The research casts lights on the promise of an old drug (disulfiram) for a new application.
Professor Yongzhuo Huang
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Read the Original
This page is a summary of: Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy, Advanced Functional Materials, July 2017, Wiley,
DOI: 10.1002/adfm.201700403.
You can read the full text:
Contributors
The following have contributed to this page
